534 drugs will be reviewed through the National Medical Insurance Drug Catalog by 2025.

The National Healthcare Security Administration announced the preliminary results of the review of the 2025 National Healthcare Drug List on the 12th, with 534 drugs passing the review. The number of drugs applied for exceeded that of 2024. It is worth noting that this year's list adjustment includes the addition of a special list for innovative drugs covered by commercial insurance, which can be applied for simultaneously with the basic medical insurance drug list. The application information for the commercial insurance innovative drug list involves 141 drug names, and after preliminary review, 121 drugs passed the formal review.